Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
grade C 108.35 0.37% 0.40
NVAX closed up 0.37 percent on Wednesday, September 30, 2020, on 71 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical NVAX trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Bollinger Band Squeeze Range Contraction 0.37%
Narrow Range Bar Range Contraction 0.37%
NR7 Range Contraction 0.37%
Wide Bands Range Expansion 0.37%
Bollinger Band Squeeze Range Contraction -2.55%
Multiple of Ten Bullish Other -2.55%
Wide Bands Range Expansion -2.55%
Older End-of-Day Gignals for NVAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 3 hours ago
Up 5% about 15 hours ago
Up 3% about 15 hours ago
60 Minute Opening Range Breakout about 16 hours ago
Rose Above 10 DMA about 17 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Medicine Biopharmaceutical Infectious Diseases Coronavirus Vaccine Influenza Vaccination Rabies Influenza Vaccine Seasonal Influenza H5n1 Clinical Trials Virus Like Particle

Is NVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 189.4
52 Week Low 3.54
Average Volume 6,811,133
200-Day Moving Average 53.86
50-Day Moving Average 125.91
20-Day Moving Average 104.40
10-Day Moving Average 109.07
Average True Range 11.24
ADX 14.54
+DI 27.40
-DI 22.98
Chandelier Exit (Long, 3 ATRs ) 92.83
Chandelier Exit (Short, 3 ATRs ) 116.93
Upper Bollinger Band 122.46
Lower Bollinger Band 86.33
Percent B (%b) 0.61
BandWidth 34.61
MACD Line -2.59
MACD Signal Line -3.98
MACD Histogram 1.3848
Fundamentals Value
Market Cap 31.41 Billion
Num Shares 290 Million
EPS -0.77
Price-to-Earnings (P/E) Ratio -140.71
Price-to-Sales 13.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 122.23
Resistance 3 (R3) 123.32 119.78 119.91
Resistance 2 (R2) 119.78 116.25 119.24 119.14
Resistance 1 (R1) 114.07 114.07 116.93 112.98 118.37
Pivot Point 110.53 110.53 111.96 109.99 110.53
Support 1 (S1) 104.82 107.00 107.68 103.73 98.33
Support 2 (S2) 101.28 104.82 100.74 97.56
Support 3 (S3) 95.57 101.28 96.79
Support 4 (S4) 94.48